Is Nuvalent, Inc. (NUVL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 17.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 17.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 97.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 17.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 97.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -36.7% | |
| Return on Assets (ROA) | -20.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$275M |
| Free Cash Flow | -$275M |
| Current Ratio | 15.3 |
| Total Assets | $1.4B |
Price & Trading
| Last Close | $98.06 |
| 50-Day MA | $101.97 |
| 200-Day MA | $91.96 |
| Avg Volume | 524K |
| Beta | 1.3 |
|
52-Week Range
$55.53
| |
About Nuvalent, Inc. (NUVL)
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nuvalent, Inc. (NUVL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nuvalent, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nuvalent, Inc.'s debt ratio?
Nuvalent, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Nuvalent, Inc.'s key financial metrics?
Nuvalent, Inc. has a market capitalization of $7.6B. Return on equity stands at -36.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.